Derm Texas, Dallas, Texas, 75235, United States - 04 Sep `26Roflumilast Foam for Facial Vitiligo

Roflumilast Foam for Facial Vitiligo

Official title: An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

Status: Recruiting now

Description:

An open-label single center, proof of concept study evaluating the efficacy of Roflumilast foam 0.3% in pediatric subjects with Non-Segmental Vitiligo (NSV)

Phase: Phase 2.

What is being studied: Drug: Roflumilast topical 0.3% foam.

Who can take part: ages 2 Years to 18 Years, 20 participants planned.

Enrollment status: Open now. The study starts 01 August 2025 and expected to finish 15 June 2026.

Contact: Amanda Harvey, Study Coordinator, 2148456426, aharvey@derm-texas.com.

Source: ClinicalTrials.gov, NCT07105254 (https://clinicaltrials.gov/study/NCT07105254).

Start date: August 01, 2025

Completion date: June 15, 2026

Organizer: Derm Texas, PLLC

Contact: Amanda Harvey, Study Coordinator

Tel.: 2148456426

Email: aharvey@derm-texas.com

Link: https://clinicaltrials.gov/study/NCT07105254

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Roflumilast Foam for Facial Vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions